双(2-溴乙基)胺氢溴酸盐 | 43204-63-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 双(2-溴乙基)胺氢溴酸盐
• 中文别名: 双(2-溴乙基)胺氢溴酸
• 英文名称: bis(2-bromoethyl)amine hydrobromide
• 英文别名: N-bis(2-bromoethyl)-amine hydrobromide；Bis(2-bromoethyl)ammonium bromide；bis(2-bromoethyl)azanium;bromide
• CAS: 43204-63-3
• 化学式: Br*C₄H₁₀Br₂N
• 分子量: 311.842
• InChiKey: YHHKEXPNBPDPOW-UHFFFAOYSA-N

物化性质

• 熔点：
  203-205℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.94
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  储存条件为2-8°C，并需保存在惰性气体中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Bis(2-bromoethyl)amine hydrobromide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Bis(2-bromoethyl)amine hydrobromide
CAS number: 43204-63-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H9Br2N.BrH
Molecular weight: 311.8

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  双(2-溴乙基)胺氢溴酸盐 在 sodium carbonate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 维司力农
  参考文献：
  名称：

  正性肌力药的研究。I.3,4-二氢-6- [4-（3,4-二甲氧基苯甲酰基）-1-哌嗪基] -2（1H）-喹啉酮及其相关化合物的合成。

  摘要：

  合成了多种1-（哌嗪-1-基）-2-（1H）-喹啉酮衍生物，并对它们在犬心脏上的正性肌力活性进行了检验。其中，3,4-二氢-6-[4-（3,4-二甲氧基苯甲酰基）-1-哌嗪基]-2-（1H）-喹啉酮（XVIIb-1）显示出非常强的活性。

  DOI：

  10.1248/cpb.32.2100
• 作为产物：
  描述：

  二乙醇胺 在 氢溴酸 作用下， 生成 双(2-溴乙基)胺氢溴酸盐
  参考文献：
  名称：

  青蒿素-哌嗪-磷酰胺芥菜杂化物作为潜在抗癌剂的设计、合成和生物学评价

  摘要：

  通过高效、无催化剂的两步顺序置换合成了12 种新型青蒿素-哌嗪-磷酰胺芥 (PPM) 杂化物7a - l 。Artemisinin-PPM 杂交体7表现出比 DHA 和 VCR 更好的细胞毒性。通过引入噻唑部分显着增强了细胞毒性。Hybrid 7 h显示出比 VCR 强 7.4 倍的效力，并且是合成的最有效的化合物，也是最具选择性的（选择性指数 = 16）。

  DOI：

  10.1002/cmdc.202200239

文献信息

• REMEDIES OR PREVENTIVES FOR AIDS
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0878194A1

  公开（公告）日：1998-11-18

  The present invention is to provide the combined use of one kind or two or more kinds of a quinolone carboxylic acid having anti-HIV activity and one kind or two or more kinds of a reverse transcriptase inhibitor or HIV protease inhibitor, and an AIDS therapeutic agent or preventive agent containing as its active ingredients one kind or two or more kinds of a quinolone carboxylic acid having anti-HIV activity and one kind or two or more kinds of a reverse transcriptase inhibitor or HIV protease inhibitor.

  本发明提供了一种或两种或两种以上具有抗HIV活性的喹诺酮羧酸与一种或两种或两种以上的逆转录酶抑制剂或HIV蛋白酶抑制剂的联合使用，以及一种包含作为其活性成分的抗HIV活性的喹诺酮羧酸和一种或两种或两种以上的逆转录酶抑制剂或HIV蛋白酶抑制剂的艾滋病治疗剂或预防剂。
• Phosphorus-31 NMR and chloride ion kinetics of alkylating monoester phosphoramidates
  作者：Kristin M. Fries、Richard F. Borch

  DOI：10.1021/jm00106a014

  日期：1991.2

  conditions. Halide ion kinetics were used to determine the rate of aziridinium ion formation. The solvolysis rates showed the expected dependence upon substitution at the reactive nitrogen; comparison of 4a with phosphoramide mustard (1a) indicated that replacement of the amino group by alkoxy decreased the solvolysis rate by approximately 10-fold. The rate of conversion of starting compound (4a-d) to solvolysis

  31 P NMR光谱用于研究模型生理条件下一系列新型烷基化单酯氨基磷酸酯（4a-d）的溶剂分解动力学。卤离子动力学用于确定叠氮鎓离子形成的速率。溶剂分解速率显示出预期的对反应性氮取代的依赖性。将4a与磷酰胺芥末（1a）进行比较表明，用烷氧基取代氨基会使溶剂分解速率降低约10倍。起始化合物（4a-d）转化为溶剂分解产物的速率基本上等于卤离子的释放速率，这表明叠氮鎓离子是短寿命的中间体。在不存在和存在捕集剂（二甲基二硫代氨基甲酸酯）的情况下进行的1H NMR和31P NMR动力学实验证实，叠氮鎓离子的寿命太短，无法通过NMR观察到。还测试了这些化合物对L1210白血病和B16黑色素瘤细胞的细胞毒性。单烷基化剂4c和4d没有活性，4a具有弱的细胞毒性，而4b的活性与磷酰胺芥菜相当。
• Silver alkoxide and amino N-heterocyclic carbenes; syntheses and crystal structures
  作者：Ian S. Edworthy、Mark Rodden、Shaheed A. Mungur、Kate M. Davis、Alexander J. Blake、Claire Wilson、Martin Schröder、Polly L. Arnold

  DOI：10.1016/j.jorganchem.2005.07.063

  日期：2005.12

  [Ag(HL2a)Br], affords imidazolium complexes salts [H2L1a][AgCl2] and [Ag(H2L2a)Br][AgBr2] that retain the Ag(I) centre as complex counterions. The single crystal X-ray structures of these salts have been determined and show the silver(I) cations are now incorporated into ladders or chains as silver(I) halo-anions, and a silver amine dative bond is present in the latter complex.

  通过直接脱质子化[HOCR 1 R 2 CH 2（1-HC NCHCHNR} ））] [X]，H 2 L 1 X（X = Br，I），[H 2 NR 1 CHR 2 CHR 2（1-HC NCHCHNR}）] [Br] 2 H 3 L 2 X 2（X = Cl，Br）和[H 2 N CH 2 CH 2（1-HC [NCHCHNMes]）} 2 ] [X] 3 H 4L 3 X 3（X ＝ Cl，Br）。氧化银（I）具有足够的碱性，可以使L 1配体前体之一以外的所有咪唑鎓和醇官能团均去质子化，从而提供由软供体稳定的烷醇银配合物[Ag（L 1）]的罕见实例。卡宾。L 1的另一种络合物的特征是卡宾醇加合物[Ag（HL 1）2 I]。氧化银（I）与氨基咪唑鎓前体的类似反应可提供具有潜在双齿L 2配体的氨基银卡宾[Ag（HL 2）Br]和[Ag（HL 3）X]（X = Cl，Br ）与潜在的三
• Studies on positive inotropic agents. VI. Synthesis of 1-aromatic ring substituted 4-(3,4-dimethoxybenzoyl)piperazine derivatives.
  作者：HIDENORI OGAWA、SHIGEHARU TAMADA、TAKAFUMI FUJIOKA、SHUJI TERAMONO、KAZUMI KONDO、SHUJI YAMASHITA、YOUICHI YABUUCHI、MICHIAKI TOMINAGA、KAZUYUKI NAKAGAWA

  DOI：10.1248/cpb.36.2401

  日期：——

  A series of 1-aromatic ring substituted 4-(3, 4-dimethoxybenzoyl)piperazines were synthesized and examined for positive inotropic activity on the canine heart. Among them, 6-[4-(3, 4-dimethoxybenzoyl)-1-piperazinyl]-3-methyl-1H, 3H-quinazolin-2, 4-dione was found to have a potent activity.

  合成了一系列带有1-芳环取代的4-(3,4-二甲氧基苯甲酰)哌嗪化合物，并对其在大犬心脏上的正性肌力活性进行了研究。其中，6-[4-(3,4-二甲氧基苯甲酰)-1-哌嗪基]-3-甲基-1H,3H-喹唑啉-2,4-二酮展现出强大的活性。
• Phosphoramidate analogs of 2'-deoxyuridine
  申请人：University of Rochester

  公开号：US05233031A1

  公开（公告）日：1993-08-03

  The present invention provides a series of cytotoxic phosphoramidate analogs of 5-fluoro-2'-deoxyuridine of the general formula (I): ##STR1## wherein R.sup.1 is H, F or (C.sub.1 -C.sub.4)alkyl; R.sup.2 is CH.sub.2 CH.sub.2 X wherein X is Cl, Br, I or p-toluenesulfonyl; R.sup.3 is (C.sub.1 -C.sub.4)alkyl or CH.sub.2 CH.sub.2 X wherein X is Cl, Br, I or p-toluenesulfonyl; or wherein R.sup.2 and R.sup.3, taken together with the N atom, can be a 5- or 6-membered heterocyclic ring which is aliphatic or aliphatic interrupted by a ring oxygen or a second ring nitrogen; R.sup.4 is H, one equivalent of a pharmaceutically-acceptable cation or (4,4,6-trimethyltetrahydro-1,3-oxazin-2-yl)ethyl, and the pharmaceutically-acceptable salts thereof.

  本发明提供了一系列细胞毒性的5-氟-2'-脱氧尿嘧啶的磷酰胺类似物，其一般式为(I)：##STR1##其中R.sup.1为H，F或(C.sub.1 -C.sub.4)烷基；R.sup.2为CH.sub.2 CH.sub.2 X，其中X为Cl，Br，I或对甲苯磺酰基；R.sup.3为(C.sub.1 -C.sub.4)烷基或CH.sub.2 CH.sub.2 X，其中X为Cl，Br，I或对甲苯磺酰基；或其中R.sup.2和R.sup.3，与N原子一起，可以是一个5-或6-成员杂环，其为脂肪族的或被一个环氧原子或第二个环氮原子中断的脂肪族；R.sup.4为H，一个等效的药用阳离子或(4,4,6-三甲基四氢-1,3-噁唑啉-2-基)乙基，以及其药用盐。